（编辑 袁冠琳） 证券日报网讯 匠心家居7月29日在互动平台回答投资者提问时表示，公司在越南的产能布局遵循"轻资 产起步+重资产择机切入"的策略。当前租赁厂房的方式，有利于快速形成产能、降低前期重资产投入 风险，并保持战略调整的灵活性。 ...

人民币贬值受益+智能家居+养老概念+一带一路 来源：新浪证券-红岸工作室 1、根据2024年年报，公司海外营收占比为99.49%，受益于人民币贬值。 7月29日，匠心家居跌0.95%，成交额8223.81万元，换手率0.61%，总市值201.55亿元。 2、公司的主营业务为从事智能电动沙发、智能电动床及其核心配件的研发、设计、生产和销售。公司 的主要产品为单椅、组合沙发、机构件、电机、电控装置。 异动分析 3、公司进军康养产业，产品有康养机构智能床，多体位康复治疗床，家里护用智能床等产品。 4、根据2025年4月11日互动易回复：公司越南生产基地自建成以来，始终坚持本地化建设、本地化运营 的原则，在人员管理、工艺制造、设备投入及供应链协同等方面，已具备完整的独立制造能力。公司核 心产品均在越南境内完成开发、加工与装配，不属于"转口贸易"模式。公司将继续秉持合规、透明、高 效的运营理念，持续提升全球供应链体系的稳定性与交付能力。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-507.01万，占比0.06%，行业排名46/73，连续2日被主力资金减仓； ...

Investment Rating - The report provides a positive outlook on various sectors, indicating a stable recovery in the home furnishing and paper packaging sectors, while new tobacco and packaging sectors show robust growth [3][4]. Core Insights - The home furnishing sector is expected to see marginal improvement in domestic demand due to government support for consumption upgrades, with a focus on companies with high dividend yields and growth certainty for 2025 [5][10]. - The new tobacco sector is experiencing growth, particularly in heated tobacco products (HTP), with significant sales increases reported in Europe and a growing user base for IQOS [11]. - The paper packaging sector is facing a gradual recovery in pulp prices, with a focus on companies that maintain strong market positions and high dividends [12]. - The light consumer goods and pet food sectors are under pressure, but there are opportunities in innovative product launches and channel expansion [15]. - The two-wheeler sector is poised for a rebound with government subsidies and new standards expected to drive demand [16][17]. Summary by Sections Home Furnishing - Domestic sales are expected to improve due to government initiatives, with a focus on companies with strong growth prospects and high dividends [5][10]. - Export figures show a slight increase in June, but a cumulative decline for the first half of the year [10]. New Tobacco - HNB sales increased by 10.5% year-on-year, with a growing user base for IQOS [11]. - The regulatory environment in the U.S. is tightening, which may benefit compliant market players [11]. Paper Packaging - Pulp prices have shown slight increases, but overall market conditions remain challenging [12]. - Companies with strong market positions and dividend policies are recommended for investment [12]. Light Consumer Goods & Pet Food - The sector is facing challenges, but there are opportunities in new product launches and expanding distribution channels [15]. - Online sales data indicates mixed performance across different product categories [23]. Two-Wheeler - The sector is expected to benefit from government subsidies and new regulations, with a focus on companies that can leverage these changes for growth [16][17]. - Recent data shows a significant number of electric bikes being replaced under the subsidy program [26][27].

Core Viewpoint - Gao Nan's managed funds reported significant growth in the second quarter, with a total management scale of 15.326 billion yuan, an increase of nearly 30% from the previous quarter [1] Fund Performance - Gao Nan's flagship fund, Yongying Ruixin, saw an increase of nearly 1.6 billion yuan in scale during the second quarter, reaching 5.016 billion yuan [1] - The net asset value of Yongying Ruixin Mixed A Fund was 1.4545 yuan at the end of the reporting period, with a net value growth rate of 10.12%, compared to a benchmark return of 1.50% [1] Portfolio Composition - The top ten holdings of Yongying Ruixin as of the end of the second quarter included Pop Mart (09992), Zhongji Xuchuang (300308), Kangfang Biotech (09926), Xinyi Sheng (300502), Jiangxin Home (301061), Xinda Biotech (01801), Weichai Heavy Industry (000880), Baijie Shenzhou (688235), San Sheng Pharmaceutical (01530), and Zijin Mining (601899) [1] - New additions to the portfolio included Zhongji Xuchuang, Xinyi Sheng, Xinda Biotech, Weichai Heavy Industry, San Sheng Pharmaceutical, and Zijin Mining, while Kangfang Biotech and Baijie Shenzhou were increased [3] Macroeconomic Environment - The overall economic operation in China remained stable in the second quarter, with resilient industrial production and high levels of infrastructure and manufacturing investment [3] - The central bank implemented measures such as reserve requirement ratio cuts and interest rate reductions to stabilize the market and expectations [3] Market Analysis - The Shanghai Composite Index rose by 3.26% in the second quarter, despite experiencing significant volatility [3] - The market saw a notable differentiation in asset performance, with sectors like innovative pharmaceuticals, artificial intelligence, and finance showing significant excess returns [3] Investment Strategy - The investment strategy emphasized bottom-up stock selection, focusing on company growth potential and earnings realization [4] - The fund aims to diversify industry concentration while capturing growth opportunities, and it also considers stocks with a safety margin and potential for future improvement [4]

Investment Rating - The industry investment rating is "Hold" [1] Core Views - The report highlights a significant divergence in performance among companies as they release their semi-annual earnings forecasts, with some companies showing remarkable growth while others face declines [3][19] - Key drivers for growth include market expansion, product upgrades, operational efficiency improvements, and effective cost control [21][24] Summary by Sections Semi-Annual Earnings Forecasts - Jiangxin Home reported a net profit of 410-460 million yuan for H1 2025, representing a year-on-year growth of 43.70%-61.23% [21] - Aorijin expects a net profit of 850-960 million yuan for H1 2025, with a growth rate of 55%-75% [21] - Zhongshun Jierou anticipates a net profit of 140-160 million yuan, reflecting a growth of 59.85%-82.68% [24] - Saifutian forecasts a turnaround with a net profit of 2.55-3.80 million yuan, compared to a loss of 12.49 million yuan in the previous year [23] Market Performance - From July 14 to July 18, 2025, the Shanghai Composite Index rose by 0.69%, while the ShenZhen Component Index increased by 2.04% [25] - The light industry manufacturing index rose by 0.08%, ranking 21st among 31 sectors, while the textile and apparel index increased by 0.24%, ranking 19th [25] Key Data Tracking - Real estate data shows a significant decline in property transactions, with a 35.98% decrease in the transaction area of commercial housing in major cities [34] - The price of cotton in China is reported at 15,508 yuan per ton, with a week-on-week increase of 1.59% [12] - The report indicates a notable increase in furniture sales, with June 2025 sales reaching 20.77 billion yuan, a year-on-year increase of 28.7% [9]

Investment Rating - The report maintains a positive outlook on the light industry and paper-making sector for the mid-2025 earnings forecast, indicating a favorable investment rating for these industries [1]. Core Insights - The report highlights a divergence in performance within the export sector for Q2 2025, with companies that have a global supply chain showing resilience against external tariff disruptions. Notable performers include Jiangxin Home, Jiayi Co., and Tianzhen Co. [4][5]. - The two-wheeler segment is expected to benefit from government subsidies and new standards, with companies like Yadi Holdings and Aima Technology showing strong growth potential [4]. - The light consumer goods sector is characterized by a robust domestic demand, particularly in personal care products, with companies like Baiya Co. and Dengkang Oral Care expected to perform well [4]. - The packaging industry is undergoing consolidation, with leading companies experiencing a slowdown in capital expenditure, indicating a shift towards a harvest phase [4]. - The home furnishing sector is facing short-term order impacts due to the pause in government subsidies, but long-term growth is anticipated through market integration and new product categories [4]. - The paper-making sector is expected to see stable profitability due to low raw material costs and improved supply-demand dynamics [4]. Summary by Sections Export Sector - Q2 2025 shows performance divergence due to increased external disruptions, with companies like Jiangxin Home expected to see a 40%+ growth in net profit [5][6]. - Jiayi Co. anticipates a 30%+ revenue increase, while Tianzhen Co. is expected to recover orders significantly [4][5]. Two-Wheeler Sector - Companies like Aima Technology and Ninebot are projected to grow by 20% and 50% respectively in Q2 2025, driven by new product launches and market demand [8][9]. Light Consumer Goods - The sector is expected to show resilience, with companies like Chaohongji and Baiya Co. projected to grow by 20% and 2% respectively in revenue [10][11]. Packaging Industry - The report notes a continued consolidation trend, with companies like Yutong Technology and Baosteel Packaging expected to maintain stable revenue growth [12][14]. Home Furnishing Sector - The sector is facing challenges due to subsidy pauses, but companies like Mousse and Zhizhong Home are expected to adapt and show growth in the long term [13][15]. Paper-Making Sector - The report indicates stable profitability for the paper-making sector, with companies like Sun Paper and Huawang Technology expected to benefit from improved market conditions [17].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Viewpoints - The company reported a strong performance in H1 2025, with a net profit attributable to shareholders expected to be between 410-460 million yuan, representing a year-on-year growth of 43.70%-61.23% [3] - The growth in performance is attributed to continuous optimization of market layout, product structure upgrades, improved internal operational efficiency, and effective control of period expenses [3] - 78% of the company's products are exported to the US via Vietnam, indicating limited impact from reciprocal tariffs [3] - The company is positioned as a significant ODM supplier in the global smart electric sofa and bed industry, with a robust overseas capacity layout and an integrated supply chain [4] Financial Projections - Revenue projections for 2025-2027 are 3.379 billion, 4.141 billion, and 4.785 billion yuan, with year-on-year growth rates of 32.6%, 22.5%, and 15.6% respectively [4] - Net profit attributable to shareholders is projected to be 902 million, 1.094 billion, and 1.268 billion yuan for the same period, with year-on-year growth rates of 32.0%, 21.3%, and 15.9% respectively [4] - The expected EPS for 2025-2027 is 4.14, 5.03, and 5.83 yuan, with corresponding P/E ratios of 22, 18, and 15 [4]

Core Viewpoint - The article highlights the ongoing strong performance of the innovative drug sector, with several fund managers increasing their allocations to this area, indicating a positive outlook for the future despite potential adjustments and volatility ahead [2][3][8]. Group 1: Fund Managers' Adjustments - Fund manager Fu Pengbo has increased allocations to the pharmaceutical sector, particularly in innovative drugs and traditional medicine benefiting from AI, while also adjusting positions in the export chain [4]. - Fund manager Gao Nan has shifted focus towards TMT (Technology, Media, and Telecommunications) and innovative drugs, with significant growth in fund size, indicating a strategic pivot in investment focus [5][6]. - Both fund managers express confidence in the continuation of the innovative drug market's upward trend, emphasizing the importance of evaluating company performance through upcoming mid-year reports [4][10]. Group 2: Market Dynamics and Trends - The innovative drug sector is seen as a necessary evolution rather than an option, with Chinese companies positioned to benefit from global competition and transparency in drug development [9][10]. - Factors contributing to the success of Chinese innovative drugs include high research efficiency, lower operational costs, and a well-established industry chain that supports rapid market entry and commercialization [9]. - The article notes that while the innovative drug sector has strong long-term potential, it has already experienced significant gains, suggesting that market corrections and fluctuations are likely in the near future [3][11].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [5]. Core Views - The company is positioned as a rare alpha stock in the light industry sector, with strong growth prospects driven by overseas market expansion, product upgrades, and operational efficiency improvements [1][2][4]. - The company forecasts significant profit growth for 2025, with expected net profit ranging from 4.1 to 4.6 billion yuan for the first half of the year, representing a year-on-year increase of 44% to 61% [1][4]. Summary by Sections Revenue and Profit Growth - The company is optimizing its market layout by actively expanding into overseas markets, particularly enhancing its core channels in North America, which supports stable revenue growth [2]. - Continuous investment in R&D and product optimization is leading to an increase in the sales proportion of high-value-added products, thereby improving overall gross margins and profitability [2]. - The company is enhancing internal operational efficiency through refined management practices and cost control, effectively reducing operational costs [2]. - The control of period expenses is well-managed, contributing to profit growth while maintaining core business growth [2]. - The increase in non-recurring profit is minimal, indicating that the growth in net profit is primarily driven by core business activities [2]. Overseas Operations - The company's manufacturing base in Vietnam is handling a significant portion of its export orders, especially for key products aimed at the North American market [3]. - The production capacity in Vietnam is currently high but adjustable, allowing for quick responses to order fluctuations [3]. - The company has stable labor conditions in Vietnam and focuses on employee management and incentives, avoiding labor shortages [3]. - Future business growth has been pre-planned, including space expansion and equipment upgrades, with expansion measures to be implemented based on actual order growth and customer demand [3]. Financial Projections - The report maintains profit forecasts for the company, projecting net profits of 9.1 billion, 11.1 billion, and 13.7 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 22, 18, and 14 [4]. - Revenue is expected to grow significantly, with projected figures of 1,921.46 million yuan in 2023, increasing to 5,035.79 million yuan by 2027, reflecting a compound annual growth rate of approximately 22.24% [4][10]. - The company's net profit is projected to grow from 407.39 million yuan in 2023 to 1,369.72 million yuan in 2027, indicating a strong growth trajectory [4][11].

Investment Rating - The report maintains a "Buy" rating for the company [8][13]. Core Insights - The company's performance continues to validate its business model and operational capabilities, with a significant year-on-year growth in net profit for Q2 2025, expected to be between 216 million to 266 million yuan, representing a 46.6% increase [13]. - The non-net profit for Q2 2025 is projected to be between 214 million to 264 million yuan, with a year-on-year growth of 65.3% [13]. - The company is actively expanding its overseas market presence, particularly in North America, enhancing brand visibility and retail network coverage, which supports stable revenue growth [13]. - Continuous investment in R&D and product optimization has led to an increase in the sales proportion of high-value-added products, improving overall gross margins and profitability [13]. - The report highlights that the actual operating quality is better than indicated by external disruptions, with the growth in net profit primarily driven by core business activities [13]. Financial Summary - Total revenue is projected to grow from 1,921 million yuan in 2023 to 5,054 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of 31.4% to 19.4% [6][14]. - Net profit attributable to the parent company is expected to increase from 407 million yuan in 2023 to 1,413 million yuan in 2027, with a notable growth rate of 67.6% in 2024 [6][14]. - Earnings per share (EPS) is forecasted to rise from 1.87 yuan in 2023 to 6.50 yuan in 2027 [6][14]. - The return on equity (ROE) is anticipated to improve from 13.6% in 2023 to 20.8% in 2027 [6][14]. - The price-to-earnings (P/E) ratio is projected to decrease from 48.67 in 2023 to 14.03 in 2027, indicating an attractive valuation over time [6][14]. Market Data - The target price for the company's stock is set at 106.87 yuan, with the current price being 91.13 yuan [8]. - The company's market capitalization is approximately 19,828 million yuan [9]. - The stock has a 52-week price range of 39.52 to 91.13 yuan [9].